Last December, the company raised its quarterly payout for the 16th consecutive year. The dividend yield investors could ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Metro Bank Holdings PLC (NYSE: MCB) (LSE:MTRO) results are flagged by market analyst Victoria Scholar at Interactive Investor ...

A string of blunders led to the value of Novo Nordisk plummeting last week. Could a new weight-loss pill help it regain its ...